Objectives: Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions confined to the ducts and lobules of the breast, which differ in histological grade and biological potential. As the principal finding is microcalcifications, the presence of DCIS is more frequent in populations that are submitted to mammography screening. This condition is usually treated with local surgery and adjuvant radiotherapy. The use of sentinel node biopsy is reserved for large tumors when the risk of invasion is higher and in radical surgeries. Methodology: We have performed a retrospective analysis of 157 cases of DCIS diagnosed by percutaneous biopsy treated in our institution between 2011 and 2013. All the patients had an initial biopsy and had a definitive surgery in our hospital. We have initially reviewed the age, grade, the presence of necrosis, type of surgery, and the presence of axillary staging by sentinel node biopsy (SNB) or axillary sampling (AS). Results: From 167 cases we saw 18 cases that initially were diagnosed as DCIS, but were confirmed to be invasive after surgery. Most of our population were more than 50 years old (64%). Interestingly 30% of our patients were between 40-49 years, a range that is not contemplated in the program of mammographic screening determined by the National Cancer Institute (INCA). Most of our patients were treated with partial mastectomy (70%) and radical surgery in 30%. In 9% of the cases, a AS was performed and, in 20%, SNB was performed. There was no lymph node positive in our analyses. Conclusion: DCIS is an important disease and our data showed that the prevalence in the range age 40-49 is high and the INCA screening programme should be reviewed. The use of axillary staging should be discouraged for DCIS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.